---
description: Harvard and MIT-developed AI clinical decision support tool handles 8.5M consultations per month and scored 100 percent on USMLE with valuation surging from 3.5B to 12B in six months signaling that physicians will adopt AI tools that fit existing workflows
type: claim
domain: health
created: 2026-02-17
source: "OpenEvidence announcements 2025-2026; CNBC January 2026; Sutter Health integration February 2026"
confidence: likely
---

# OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years

OpenEvidence is the breakout story in clinical AI. Developed by Harvard and MIT researchers, it operates across 10,000+ hospitals, handles 8.5 million clinical consultations per month, and was the first AI to score 100% on the USMLE. Strategic content partnerships with NEJM and JAMA ground its responses in peer-reviewed evidence.

The valuation trajectory reflects market conviction: $3.5B (Series B, July 2025) → $6.1B (October 2025) → $12B (Series D, January 2026, co-led by Thrive Capital and DST Global). In February 2026, Sutter Health announced integration directly into Epic workflows, signaling the shift from standalone tools to EHR-embedded clinical decision support.

What makes this significant is the adoption speed. Reaching 40% of US physicians in ~2 years is unprecedented for any clinical technology. The lesson: physicians adopt AI tools that (1) answer clinical questions faster than existing alternatives, (2) cite verifiable evidence, and (3) fit into existing workflows rather than requiring new ones. OpenEvidence succeeded where previous clinical AI failed because it treated the physician as the user, not the patient.

The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments.


### Additional Evidence (extend)
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*

OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from 8.5M in 2025, representing 2,000%+ YoY growth), valuation increased from $3.5B to $12B in months, reached 1M consultations in a single day (March 10, 2026 milestone), used across 10,000+ hospitals. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight/explainability—trust barriers persist even among heavy users.

---

Relevant Notes:
- [[centaur team performance depends on role complementarity not mere human-AI combination]] -- OpenEvidence is the clinical centaur: AI provides evidence synthesis, physician provides judgment
- [[knowledge scaling bottlenecks kill revolutionary ideas before they reach critical mass]] -- OpenEvidence solved clinical knowledge scaling by making evidence retrieval instant

Topics:
- livingip overview
- health and wellness
